A phase 1/2, open-label, multicenter study to investigate the safety, pharmacokinetics, and efficacy of fadraciclib (CYC065), an oral CDK2/9 inhibitor, in subjects with advanced solid tumors and lymphoma
医学
内科学
肿瘤科
癌症
曲妥珠单抗
药理学
癌症研究
乳腺癌
作者
S. Piha-Paul,Do‐Youn Oh,Elena Garralda,María Vieito,J. Huang,M. Kirschbaum,M. Villanona-Calero